[{"orgOrder":0,"company":"Biopharmaceutical Research Company","sponsor":"Open Book Extracts","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Biopharmaceutical Research Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Biopharmaceutical Research Company \/ Biopharmaceutical Research Company","highestDevelopmentStatusID":"1","companyTruncated":"Biopharmaceutical Research Company \/ Biopharmaceutical Research Company"},{"orgOrder":0,"company":"Biopharmaceutical Research Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Biopharmaceutical Research Company","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Biopharmaceutical Research Company \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biopharmaceutical Research Company \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Biopharmaceutical Research Company

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : BRC-002 (cannabidiol) is a first-in-class therapeutic product candidate aiming to address pain and co-morbidities of Complex Regional Pain Syndrome.

                          Brand Name : BRC-002

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 03, 2024

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The partnership with BRC, supports the study of Delta-9 THC products and formulations, allowing OBX to identify the phase appropriate, optimal products for formulations including Delta-9-tetrahydrocannabinol.

                          Brand Name : Delta-9 THC

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 14, 2022

                          Lead Product(s) : Tetrahydrocannabinol

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Recipient : Open Book Extracts

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank